anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
While essential hypertension (HTN) is very prevalent, pulmonary arterial hypertension (PAH) is very rare in the general population. However, due to progressive heart failure, prognoses and survival rates are much worse in PAH. Patients with PAH are at a higher risk of developing supraventricular arrhythmias and malignant ventricular arrhythmias. The latter underlie sudden cardiac death regardless of the mechanical cardiac dysfunction. Systemic chronic inflammation and oxidative stress are causal factors that increase the risk of the occurrence of cardiac arrhythmias in hypertension. These stressful factors contribute to endothelial dysfunction and arterial pressure overload, resulting in the development of cardiac pro-arrhythmic conditions, including myocardial structural, ion channel and connexin43 (Cx43) channel remodeling and their dysfunction. Myocardial fibrosis appears to be a crucial proarrhythmic substrate linked with myocardial electrical instability due to the downregulation and abnormal topology of electrical coupling protein Cx43. Furthermore, these conditions promote ventricular mechanical dysfunction and heart failure. The treatment algorithm in HTN is superior to PAH, likely due to the paucity of comprehensive pathomechanisms and causal factors for a multitargeted approach in PAH. The intention of this review is to provide information regarding the role of Cx43 in the development of cardiac arrhythmias in hypertensive heart disease. Furthermore, information on the progress of therapy in terms of its cardioprotective and potentially antiarrhythmic effects is included. Specifically, the benefits of sodium glucose co-transporter inhibitors (SGLT2i), as well as sotatercept, pirfenidone, ranolazine, nintedanib, mirabegron and melatonin are discussed. Discovering novel therapeutic and antiarrhythmic strategies may be challenging for further research. Undoubtedly, such research should include protection of the heart from inflammation and oxidative stress, as these are primary pro-arrhythmic factors that jeopardize cardiac Cx43 homeostasis, the integrity of intercalated disk and extracellular matrix, and, thereby, heart function.
BACKGROUND: Although beta blockers, such as metoprolol, have been widely used in the management of vasovagal syncope (VVS), their efficacy remains debated, with larger studies showing limited benefit. Identifying patient-specific characteristics that predict a positive response to metoprolol could optimize its use. This study aims to investigate the key factors that may determine which VVS patients are suitable candidates for metoprolol treatment.
METHODS: This retrospective study was conducted at a single center. Patients diagnosed with VVS and treated with metoprolol for a minimum of three months were included. A 50% reduction in syncope symptom score (SS) after three months of metoprolol treatment was used to define metoprolol responders, while those who did not achieve this reduction were classified as non-responders. After a three-month follow-up, patients were divided into two groups: responders and non-responders. Baseline data-including age, gender, comorbidities, laboratory tests, and the type of VVS-were analyzed for each patient. Changes in heart rate (HR) and blood pressure during the head-up tilt test (HUTT) were also evaluated between the two groups. Logistic regression analysis was performed to identify potential predictors of metoprolol response, and receiver operating characteristic (ROC) curve analysis was used to assess the value of these predictors in selecting potential responders.
RESULTS: A total of 168 VVS patients were enrolled between January 2016 and December 2020. Of these, 100 patients responded positively to metoprolol, while 68 did not. No significant differences in baseline characteristics or HUTT results were observed between the two groups (p > 0.05). However, responders exhibited a significantly higher peak HR compared to non-responders during the HUTT (120.13 ± 19.33 vs. 106.60 ± 22.32, p < 0.001). The increase in HR was also more pronounced in responders (0.60 ± 0.23 vs. 0.41 ± 0.25, p < 0.001). Additionally, HR variability was significantly greater in responders than in non-responders (16.18 ± 5.51 vs. 12.61 ± 5.50, p < 0.001).
CONCLUSION: Higher peak HR, larger increases in HR, and greater HR variability during the HUTT may serve as reliable predictors of a positive response to metoprolol in patients with VVS.
Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
Pancreaticoduodenectomy (PD) with lymphadenectomy is the current treatment of pancreatic ductal adenocarcinoma (PDAC). The optimal lymphadenectomy during PD (standard versus extended) has been largely debated during the last two decades. Four randomized controlled trials (RCTs) published afterward reported no survival benefit, and no arguments could be presented based on the evidence of these studies to support the role of extended lymphadenectomy during PD. A similar conclusion was underlined also in two meta-analyses, the first from Michalski et al., in which 3 RCTs were analyzed, and the second from Iqbal et al., in which both RCTs and cohort studies were included, both of which showed no benefit of extended lymphadenectomy. However, the definition of lymphadenectomy varied considerably between the RCTs. For this reason, in 2014, the International Study Group on Pancreatic Surgery (ISGPS) defined the "standard lymphadenectomy" during PD for PDAC. Lymphadenectomy should include the removal of the hepatoduodenal ligament nodes (stations 5, 6, 12b1, 12b2, 12c according the classification of Japanese Pancreas Society), nodes along the hepatic artery (station 8a), the posterior surface of the pancreatic head (station 13a and 13b), the superior mesenteric artery (14a right lateral side, 14b left lateral side) and nodes of the anterior surface of the pancreatic head (stations 17a and 17b). Para-aortic lymph nodes (PALN; station 16) are considered as "extra-regional" lymph nodes. Some questions about PALN still remain open: a) should the removal of station 16 be routinely included in the standard lymphadenectomy during PD for PDAC? b) in case of removal of station 16 and intraoperative demonstration of PALN metastases at frozen section, should PD be avoided ? Several retrospective reports described that the prognosis of patients with metastatic PALN is significantly worse if compared with patients with negative PALN. Two recent-metaanalyses have been published on this topic, confirming that PALN metastases correlated with poor prognosis in patients with PDAC. However, these meta-analyses concluded that, due to the presence of some long survivors even in cases of PALN metastases, the definitive avoidance of PD in these cases needs further investigation. Until now, no consensus in case of intraoperative metastatic PALN has been reached. Moreover, it's not still clear if the removal of PALN during PD should be routinely performed. Until now, no randomized studies comparing PD with or without removal of PALN have been published. In 2014, during the consensus meeting of ISGPS, there was extensive discussion about PALN removal: no strong recommendation was formulated on dissecting station 16 routinely and it was not included in standard lymphadenectomy. For this reason, we decided to plan this multicentric RCT that compares upfront PD with and without the removal of PALN, in order to evaluate if their removal should be routinely included in standard lymphadenectomy during PD for PDAC.
This project will employ a mixed methods approach, combining quantitative and qualitative data collection methods within quarters 4 to 8. The quantitative method includes using the Motivation, Engagement, and Thriving in User Experience (METUX), health measures (i.e., blood pressure measurements), and telemetry to assess user engagement, adherence rates, and health outcomes in CardioCare Quest. The qualitative method will be used to identify key constructs such as motivation, engagement, and overall well-being and choose relevant metrics for each construct, including surveys for motivation, thematic analysis of quotes for engagement, and experience sampling for well-being.
Participants received a single intravenous (IV) infusion of eli-cel (also referred to as Lenti-D Drug Product) on Day 1 at a dose of \> or = 5.0\*10\^6 CD34+ cells/kilogram (kg). All participants received myeloablative conditioning with busulfan and fludarabine over a number of days prior to drug product infusion.
Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
FIELD: medicine. ^ SUBSTANCE: method for the recovery of high-purity and completely soluble partially deacetylated chitin polymer of deacetylation degree (DD) 30-60 % involves the stages: neutralisation of partially deacetylated chitin; dissolution of partially deacetylated chitin in an acid; removal of undissolved particles by sequential filtration stages; pH reduction of the solution to 8 and more; precipitation of completely dissolved and purified partially deacetylated chitin by temperature rise and salt addition where the precipitate is removed and rinsed after precipitation by filtration or centrifugation and where rinsing water and deposit temperature is 40C and higher. Also the invention refers to a neogenesis composition containing therapeutically active N-acetylglucosamine (A) and glucosamine (D) chitooligomers where the composition contains heterochitooligomers which shall meet the following criteria: said oligomers have a chain length in the range 5-20 monomer residues; each oligomer chain can have two residues of N-acetyl-D-glucosamine (AA) on any or both ends of the oligomer chain, the remained inside of the oligomer has a maximum number of the residues A; the sequence of said inside of the chain is such that the N-acetyl-D-glucosamine residue (A) does not adjoin to the other N-acetyl-D-glucosamine (A) residue (such as, e.g. AA). ^ EFFECT: biomaterial based on said compositions intensifies the bone repair and hemostasis in healing of a fractured or seriously injured bone. ^ 21 cl, 32 dwg, 9 tbl, 9 ex
The present invention provides an extract of Taiwanese wild grape ( Vitis thunbergii  var.  taiwaniana ), which is prepared by extracting one or more tissues of  Vitis thunbergii  var.  taiwaniana  with 10 wt % to 100 wt % alcohol solution or water to obtain an extract solution, and then drying said extract solution. The extract of  Vitis thunbergii  var.  taiwaniana  of the present invention has the function of regulating blood pressure, and therefore can be used to prevent and treat hypertension. The present invention also provides a method for purifying (+)-vitisin A and ampelopsin C from  Vitis thunbergii  var.  taiwaniana  and a use of these two compounds for hypertension prevention and treatment.
The invention relates to five-high controlling tablets which are a novel product currently invented for controlling various cardiovascular and cerebrovascular diseases. Before the invention is provided, Luoyishu Naoxinqing capsules produced by Xi'an QinBa Pharmaceuticals Co., Ltd. are provided for the market. The product provided by the invention is different from the capsules. A main component of the capsules is organic chromium which is a substance extracted from persimmon leaves. The main component of the tablets provided by the invention is inorganic chromium which is a natural mineral. The former product is a capsule preparation, and the latter is a tablet preparation. The action of the product provided by the invention is similar to that of the capsules. The tablets have substantial treatment effects against various cardiovascular and cerebrovascular diseases.
Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
The initial prescription and renewal of the medication order beyond 8 grams should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated. As fungal infections of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate. If this product is used for 10 days or longer, intraocular pressure should be monitored (see WARNINGS). There have been reports of bacterial keratitis associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (see PRECAUTIONS: Information for Patients). Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.
FIELD: medicine, pharmaceutical industry. SUBSTANCE: invention relates to a mixture of active components and medicinal form based on their that can be used for treatment of patients with cold sicknesses. Proposed agent is a mixture of codeine phosphate, caffeine, hexamethylenetetramine taken in the definite ratio of components. Invention provides preparing the preparation that shows the expressed antiviral activity and can be used in influenza epidemy. Also, claimed agent shows anticough effect. EFFECT: enhanced effectiveness of cold sicknesses treatment, decreased treatment time. 3 cl
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to ophthalmology. For the surgical treatment of patients with proliferative vitreoretinopathy in diabetes mellitus, vitreous quartectomy is performed, including the installation of an irrigation port, a port for the illuminator and a port for vitreoretinal tools, removal of the vitreous body (VB), isolation of the posterior hyaloid membrane using perfluororganic compound (PFOC), dissection of traction contacts of the posterior hyaloid membrane with the retina and its subsequent excision, removal of PFOC, vitreal cavity tamponade. 10–14 days before vitreous quartectomy, a single intravitreal administration of ranibizumab is performed at a dose of 0.5 mg. Vitrectomy with synechiae removal is performed using a bimanual technique with the installation of an additional fourth port for the endolighter. After removal of PFOC from the vitreal cavity, the internal boundary membrane (IBM) is contrasted, and peeling of IBM is performed. If necessary, conduct diathermal and/or endolaser coagulation of bleeding retinal vessels. Vitreal cavity tamponade is performed with an air-gas mixture CFat a concentration of 16 %.EFFECT: method ensures the achievement of a higher and stable morphofunctional result on the posterior segment of the eyeball in the postoperative period, in particular on the middle periphery and in the central zone of the retina, in one stage of vitrectomy with synechiae removal it prevents intra- and postoperative hemorrhagic complications.1 cl, 1 ex
High-fat diet (HFD) has long been recognized as risk factors for the development and progression of ulcerative colitis (UC), but the exact mechanism remained elusive. Here, HFD increased intestinal deoxycholic acid (DCA) levels, and DCA further exacerbated colonic inflammation. Transcriptome analysis revealed that DCA triggered ferroptosis pathway in colitis mice. Mechanistically, DCA upregulated hypoxia-inducible factor-2α (HIF-2α) and divalent metal transporter-1 (DMT1) expression, causing the ferrous ions accumulation and ferroptosis in intestinal epithelial cells, which was reversed by ferroptosis inhibitor ferrostatin-1. DCA failed to promote colitis and ferroptosis in intestine-specific HIF-2α-null mice. Notably, byak-angelicin inhibited DCA-induced pro-inflammatory and pro-ferroptotic effects through blocking the up-regulation of HIF-2α by DCA. Moreover, fat intake was positively correlated with disease activity in UC patients consuming HFD, with ferroptosis being more pronounced. Collectively, our findings demonstrated that HFD exacerbated colonic inflammation by promoting DCA-mediated ferroptosis, providing new insights into diet-related bile acid dysregulation in UC.
Internalized (or self) stigma develops when people with mental illness become aware of stigmatizing attitudes held by many in society about mental illness (e.g., dangerousness, incompetence, inability to work), perceive these attitudes as being legitimate, and apply them to themselves. There is substantial evidence that internalized stigma is strongly negatively linked to both the objective (e.g., social functioning) and subjective (e.g., self-esteem and well-being) components of recovery for persons with schizophrenia, and that these effects operate independent of symptom-related disability. Nevertheless, few efforts have been made to develop treatment to address this issue. Previously, the investigators were funded to develop a group-based intervention (R34MH082161) combining cognitive-behavioral therapy and narrative psychotherapy to address internalized stigma among people with severe mental illness. The purpose of the present study is to build upon the investigators' previous exploratory intervention development study by conducting an adequately-powered, randomized controlled trial of the Narrative Enhancement/Cognitive Therapy (NECT) intervention among persons with schizophrenia-spectrum disorders. The investigators will screen 500 persons at two sites (Newark, New Jersey and Indianapolis, IN) for evidence of moderate or elevated internalized stigma. They will conduct a randomized study of NECT versus supportive group therapy in a sample of 175 individuals meeting Structured Clinical Interview criteria for schizophrenia-spectrum disorders. Randomization will be stratified by baseline self-stigma severity (moderate or elevated), to ensure roughly equal numbers of participants for each stratum. Participants will complete baseline, post-treatment, 3-month post treatment and 6-month post treatment assessments of internalized stigma, psychiatric symptoms, insight, self-esteem, hopelessness, coping, narrative coherence and social functioning. The specific aims of the project are: 1) Conduct a randomized study of the effectiveness of NECT, comparing outcomes for 175 persons with schizophrenia-spectrum disorder randomly assigned to NECT or supportive group therapy, 2) Examine the mediating impact of changes in narrative coherence and in the use of problem-centered coping strategies on outcomes for persons assigned to the NECT treatment. The intervention can have important implications for enhancing usual care services to reduce disability for people with schizophrenia, and therefore has potentially important implications for improving the public health.
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to complex homeopathic agents and can be used at periodical insomnia, overfatigue, overexcitation. Homeopathic drug has Belladonna, Nux vomica, Coffee at equal mass ratio of components. Drug is made as granules saturated with components at hundred alcoholic dilutions by homeopathic procedure. An agent shows the expressed therapeutic effect at low doses. EFFECT: enhanced effectiveness of drug. 2 cl, 1 ex
PURPOSE: A stable emulsion thickening agent with reduced phase separation is provided to improve phase stability and to enhance compatibility with other compounds. CONSTITUTION: A composition contains oil phase, water phase, W/O emulsifier and O/W emulsifier. The oil phase contains isoparaffin of C12-16 and crosslinking agent. The water phase contains water, anion monomer, neutral monomer and crosslinking agent. The anion monomer is alkali metal salt, ammonium salt, and amino alcohol salt of partially or entirely chloridized 2-acrylamido-2-methylpropane-sulfonic acid(AMPS). The W/O emulsifier is polyglycerol ester, polyoxyethylene ester, or mixture thereof.
The invention provides a trypsin inhibitor which is obtained by extracting and purifying black beans. The molecular weight of the trypsin inhibitor is 20.3 kD, and PI is 4.6. The trypsin inhibitor has activity of inhibiting trypsin and has chitinase activity. The preparation method includes: smashing and degreasing black bean seeds; using buffering liquid for extraction, and using ammonium sulfate salt for separation to obtain crude protein; performing two-step chromatographic separation and purification of DEAE-FF anion exchange chromatography and Sephacryl TMS-100HR size exclusion chromatography to obtain the trypsin inhibitor. The trypsin inhibitor has obvious inhibiting effect on ligninsae and Fusarium oxysporum and has certain inhibiting effect on proliferation of tumor cells. The trypsin inhibitor can serve as a food preservative and additive and a crop spray resistant to fungus attack and can be used in auxiliary drugs for preventing and treating tumor.
Venofer 200 mg will be given every other day until the patient reaches their calculated in deficit dose. The does of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg.14 Our target Hgb will be 11.0 g/dL. The determination of the treatment duration and dosage will be based on the calculation of the iron deficit.
The inventors have discovered that a CKbeta8-1 truncation variant, CKbeta8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKbeta8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CKbeta8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CKbeta8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.
Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
Single-cell technology has allowed researchers to probe tissue complexity and dynamics at unprecedented depth in health and disease. However, the generation of high-dimensionality single-cell atlases and virtual three-dimensional tissues requires integrated reference maps that harmonize disparate experimental designs, analytical pipelines, and taxonomies. Here, we present a comprehensive single-cell transcriptome integration map of cardiac fibrosis, which underpins pathophysiology in most cardiovascular diseases. Our findings reveal similarity between cardiac fibroblast (CF) identities and dynamics in ischemic versus pressure overload models of cardiomyopathy. We also describe timelines for commitment of activated CFs to proliferation and myofibrogenesis, profibrotic and antifibrotic polarization of myofibroblasts and matrifibrocytes, and CF conservation across mouse and human healthy and diseased hearts. These insights have the potential to inform knowledge-based therapies.